Scarica l'app Stockscreener
11.56
0.13%
-0.19
Precedente Chiudi:
$11.37
Aprire:
$11.5
Volume 24 ore:
10,855
Relative Volume:
0.12
Capitalizzazione di mercato:
$279.53M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-0.2321
EPS:
-49.8
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
-0.92%
1M Prestazione:
+14.70%
6M Prestazione:
-32.61%
1 anno Prestazione:
-35.56%
Intervallo 1D:
$11.19
$11.53
Intervallo di 1 settimana:
$10.01
$11.75
Portata 52W:
$8.46
$26.50
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Confronta RNAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
11.22 | 279.53M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.89 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.53 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.37 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
246.34 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Myasthenia Gravis Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - The Globe and Mail
IBM Introduces Industry-First Software to Unify Agentic Governance and Security - The Globe and Mail
Cartesian Therapeutics holds annual stockholders meeting By Investing.com - Investing.com South Africa
Cartesian Therapeutics holds annual stockholders meeting - Investing.com
Cartesian Therapeutics Holds Annual Stockholders Meeting - TipRanks
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by Bank of America Corp DE - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Two Sigma Investments LP Reduces Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Equities Analysts Offer Predictions for RNAC FY2026 Earnings - Defense World
Nuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus
Cartesian Therapeutics (RNAC) Issues Inducement Stock Options to New Employees | RNAC Stock News - GuruFocus
Cartesian Therapeutics Awards 26,350 Stock Options to Key New Hires in Autoimmune Disease Research - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
H.C. Wainwright maintains buy rating on Cartesian Therapeutics stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - mx.advfn.com
Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study - marketscreener.com
Cartesian Therapeutics Announces First Participant Enrolled - GlobeNewswire
RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | R - GuruFocus
RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | RNAC Stock News - GuruFocus
Cartesian Therapeutics Announces First Participant Enrolled in t - GuruFocus
Cartesian Therapeutics Initiates Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis - Nasdaq
Revolutionary CAR-T Treatment Enters Phase 3 Trial After Strong Results in Myasthenia Gravis Patients - Stock Titan
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust Corp - Defense World
Q1 Earnings Forecast for RNAC Issued By HC Wainwright - Defense World
HC Wainwright Has Bearish Forecast for RNAC Q2 Earnings - Defense World
Weyerhaeuser to Sell Princeton, B.C., Lumber Mill to Gorman Group - The Globe and Mail
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Multiple Myeloma Pipeline 2025: Groundbreaking Clinical - openPR.com
Cantor Fitzgerald Comments on RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ... - Eagle-Tribune
Wells Fargo & Company MN Acquires 2,568 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics (RNAC) Poised for Growth with Strong Phas - GuruFocus
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Barclays PLC Buys 7,488 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
MetLife Investment Management LLC Invests $119,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo
Needham & Company LLC Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC) - The Globe and Mail
Cartesian Therapeutics Reports Q1 2025 Financial Results - TipRanks
Needham Maintains Buy Rating on RNAC, Lowers Price Target | RNAC Stock News - GuruFocus
RNAC Reports Strong Q1 Revenue Exceeding Expectations | RNAC Stock News - GuruFocus
Cartesian Therapeutics Inc (RNAC) Q1 2025 Earnings: EPS Loss of $(0.68) Beats Estimate, Revenue Surpasses Forecast at $1.1 Million - GuruFocus
Cartesian Therapeutics Announces Upcoming Clinical Trials and Positive Results for Descartes-08 in Autoimmune Diseases - Nasdaq
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Renaissance Technologies LLC Buys New Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cartesian Therapeutics Inc Azioni (RNAC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| English Emily | Chief Operations Officer |
Apr 15 '25 |
Option Exercise |
3.30 |
7,500 |
24,750 |
47,726 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):